A B S T R A C T Primary monolayer cultures of human umbilical vein endothelium produce prostacyclin (PGI2) in response to stimulation by thrombin, ionophore A23187, arachidonic acid, and the prostaglandin endoperoxide, PGH2. None of these treatments had a significant effect on the capacity of the endothelium to produce PGI2 in response to subsequent stimulation by PGH2. By contrast, endothelium initially exposed to thrombin, A23187, or arachidonic acid produced -37, 68, and 84% less PGI2, respectively, upon subsequent stimulation by arachidonic acid. These findings suggest that PGI2 biosynthesis in cultured endothelium results in deactivation of cyclooxygenase-hydroperoxidase but not PGI2 synthetase. To test the hypothesis that PGI2 biosynthesis alone causes deactivation of cyclooxygenase, thrombin, A23187, and arachidonic acid were added to monolayers that had been preincubated with ibuprofen (250 AM), a rapidly reversible, competitive inhibitor of this enzyme. After removal of the ibuprofen and the initial stimulus, PGI2 production in response to subsequent stimulation by arachidonic acid was maximal. These findings suggest that the metabolism of arachidonic acid itself causes a direct deactivation of cyclooxygenase. After an initial exposure to arachidonic acid, PGI2 production in response to a second stimulation by arachidonic acid was restored to -34, 69, and 74% of maximal, after recovery periods of 1, 24, and 48 h,
A B S T R A C T Primary monolayer cultures of human umbilical vein endothelium produce prostacyclin (PGI2) in response to stimulation by thrombin, ionophore A23187, arachidonic acid, and the prostaglandin endoperoxide, PGH2. None of these treatments had a significant effect on the capacity of the endothelium to produce PGI2 in response to subsequent stimulation by PGH2. By contrast, endothelium initially exposed to thrombin, A23187, or arachidonic acid produced -37, 68, and 84% less PGI2, respectively, upon subsequent stimulation by arachidonic acid. These findings suggest that PGI2 biosynthesis in cultured endothelium results in deactivation of cyclooxygenase-hydroperoxidase but not PGI2 synthetase. To test the hypothesis that PGI2 biosynthesis alone causes deactivation of cyclooxygenase, thrombin, A23187, and arachidonic acid were added to monolayers that had been preincubated with ibuprofen (250 AM), a rapidly reversible, competitive inhibitor of this enzyme. After removal of the ibuprofen and the initial stimulus, PGI2 production in response to subsequent stimulation by arachidonic acid was maximal. These findings suggest that the metabolism of arachidonic acid itself causes a direct deactivation of cyclooxygenase. After an initial exposure to arachidonic acid, PGI2 production in response to a second stimulation by arachidonic acid was restored to -34, 69, and 74% of maximal, after recovery periods of 1, 24, and 48 h, INTRODUCTION Prostacyclin (PGI2)' is a potent vasodilator, inhibitor of platelet aggregation (1) , and agonist of adenylate cyclase (2) , which is produced by vascular endothelium in response to a variety of stimuli (3, 4) . At present, very little is known regarding the mechanisms involved in the regulation of PGI2 biosynthesis in endothelium. Several years ago, both we (5) and Weksler et al. (3) observed that the capacity of endothelial cells grown in culture to produce PGI2 was not unlimited. Both primary (5) and passed (3) monolayer cultures of human umbilical vein endothelium that produced PGI2 upon stimulation with thrombin failed to respond to a second exposure to thrombin. Weksler et al. (3) also reported that monolayers stimulated first with arachidonic acid responded poorly to a subsequent stimulation by thrombin. These findings suggested several explanations, the two most likely being a productmediated negative feedback mechanism or deactivation of one or more of the enzymes of PGI2 biosynthesis. Although self-regulation of prostaglandin (PG) production by a cyclic AMP-mediated negative feed-back mechanism is an attractive hypothesis, we have conclusively demonstrated that such a mechanism is not involved in the short-term regulation of PGI2 biosynthesis in primary cultures of human umbilical vein endothelium (6) . On the other hand, Egan et al. (7, 8) have shown that microsomal as well as purified preparations of prostaglandin cyclooxygenase-hydroperoxidase (endoperoxide synthetase) become irreversibly deactivated during catalysis. Deactivation has been attributed to attack on the enzyme by an oxidizing species formed in situ by the hydroperoxidase (7). This oxidizing species has also been reported to deactivate PGI2 synthetase (9) . In light of these findings, this study was designed to determine whether deactivation of cyclooxygenase and/or PGI2 synthetase occurs in endothelium grown in culture and whether it plays a role in the regulation of PGI2 biosynthesis. Evidence presented in this paper suggests that cyclooxygenase, but not PGI2 synthetase, becomes deactivated during PGI2 biosynthesis. Preliminary results have been reported in abstract form (10) .
METHODS
Reagents. PGH2 was biosynthesized according to the method of Gorman et al. (11) . Arachidonic acid was purchased from Nu-Chek Prep., Inc. (Elysian, MN) and A23187 from Calbiochem-Behring Corp., American Hoechst Corp. (San Diego, CA). Stock solutions (10 mM) of both arachidonic acid and A23187 were prepared using dimethyl sulfoxide as the diluent; 20-Al aliquots of these solutions were kept at -80°C until use. Na ibuprofen (Motrin) was a gift from the Upjohn Co. (Kalamazoo, MI). L-Ascorbic acid, n-propyl gallate, dithiothreitol, and glutathione (reduced form) were purchased from Sigma Chemical Co. (St. Louis, MO); phenyl-methyl-sulfide (thioanisole) was from Aldrich Chemical Co. (Milwaukee, WI). The sources of other agents used are described elsewhere (4, 5, 12, 13) .
Cell culture. Primary cultures of human endothelial cells from umbilical veins were prepared by a modification (13) of the method of Jaffe et al. (14) . Confluent 
RESULTS
PGI2 synthetase. To determine whether deactivation of PGI2 synthetase occurs in cultured endothelium, we first examined the effect of the PG endoperoxide, PGH2, on PGI2 production by endothelium previously exposed to PGH2. As shown in Fig. 1 , prior exposure of the endothelium to PGH2 had no effect on the amount of PGI2 produced in response to a second stimulation by this endoperoxide. In addition, no significant decrease in PGI2 production was observed even after three successive exposures to PGH2 (data not shown). Similar results were obtained when endothelium had been pretreated with 100,M aspirin; thus, the effect of PGH2 is solely attributable to its conversion to PGI2 by PGI2 synthetase, and not to indirect stimulation of earlier steps in the biosynthetic pathway. The spond maximally to multiple stimulations by PGH2 suggests that PGI2 synthetase does not become directly deactivated as a result of the conversion of PGH2 to PGI2. To determine whether events or products generated during earlier steps in the biosynthetic pathway could deactivate PGI2 synthetase, the effect of PGH2 on PGI2 production by endothelium that had first been exposed to other stimuli was studied. Fig. 2 shows that prior stimulation of the endothelium by thrombin, the calcium ionophore A23187 or arachidonic acid had no detectable effect on the capacity of these cells to produce PGI2 in response to subsequent stimulation by PGH2. Together, these findings suggest that deactivation of PGI2 synthetase does not occur in cultured vascular endothelium. Prostaglandin cyclooxygenase-hydroperoxidase. In sharp contrast to the effect of PGH2, prior exposure of the endothelium to 4 AsM arachidonic acid markedly decreased PGI2 production in response to an immediate subsequent stimulation by the same concentration of this fatty acid ( Fig. 3 ; right). PGI2 production during a second incubation with arachidonic acid was decreased by an average of 84±2% (mean±SE of 11 experiments) as compared with the amount released in response to an initial incubation with arachidonic acid. In addition to arachidonic acid, prior exposure of the endothelium to thrombin (0.5 U/ml) or A23187 (4 AM) significantly decreased PGI2 production in response to subsequent stimulation by arachidonic acid (Fig. 3) . On average, the amount of PGI2 produced FIGURE 2 Effect of PGH2 on PGI2 production by endothelium previously exposed to thrombin, A23187, or arachidonic acid. Endothelial monolayers were incubated for 10 upon removal of the drug (17) . Experiments were therefore carried out in which the endothelium was exposed to thrombin, A23187, and arachidonic acid in the presence of ibuprofen; the monolayers were then rinsed and immediately incubated with arachidonic acid. As shown in Fig. 5 , preincubation with 250,uM ibuprofen blocked PGI2 production in response to thrombin (Fig. 5 A) , A23187 (Fig. 5 B) , or arachidonic acid (Fig. 5 C) (7, 8, 18, 19) . We have tested the effects of several antioxidants on arachidonic acid-induced stimulation of PGI2 biosynthesis with the aim of determining whether these agents can affect cyclooxygenase activity in intact cells. Neither ascorbic acid (2 mM) nor reduced glutathione (10 mM) had a significant effect on PGI2 production; however, n-propyl gallate (200 psM), methyl-phenyl-sulfide (1 mM), and dithiothreitol (10 mM) inhibited PGI2 production by 80, 43, and 97%, respectively. Preliminary studies demonstrated a dose-dependent relationship of the inhibitory effects of these agents. Each agent produced a similar inhibitory effect regardless of whether it was added before or simultaneously with arachidonic acid. The effect of methyl-phenyl-sulfide was reversible upon rinsing the endothelium; the reversibility of npropyl gallate and dithiothreitol was not determined. All of the agents studied had similar effects on PGI2 production in response to thrombin or A23187.
Recovery of responsiveness to arachidonic acid. In light of the possibility that deactivation of cyclooxygenase may play an important role in limiting PGI2 production by vascular endothelium, studies were carried out to determine the duration of this phenomenon. Since deactivation of cyclooxygenase and inhibition of its activity by aspirin result in the same net effect on PGI2 production, the capacity of the endothelium to recover from both was compared in order to provide some perspective. The protocol used in these experiments was as follows: monolayers were first incubated for 30 min at 37°C with H/H buffer alone or buffer containing 4 siM arachidonic acid or 100 AM aspirin; monolayers were then rinsed with buffer, and allowed to 'recover' for 1, 24, or 48 h in culture medium containing 20% fetal calf serum; recovery incubations were carried out in a 95% air/5% CO2 atmosphere. After the recovery period, monolayers were again rinsed and incubated for 30 min at 370C with 4 AM arachidonic acid. As shown in Table I , PGI2 production in response to a second stimulation by arachidonic acid was restored to 70% of maximal after a 48-h recovery period. Significantly less recovery to stimulation by arachidonic acid was observed in monolayers first incubated with aspirin. In three experiments, recovery of arachidonic acid-treated monolayers averaged 34±4, 69±4, and 74±2%, whereas recovery of aspirin-treated monolayers was 18+1, 36+2, and 37±2% after 1, 24, and 48 h, respectively (means±SE). Similar results were obtained when monolayers were allowed to recover in serum-free culture medium. Reduction of the aspirin concentration from 100 to 40 AM resulted in recoveries comparable to those observed with arachidonic acid-treated monolayers (data not shown). These findings suggest that the effect of deactivation, like those of aspirin, are long lasting, are likely to be irreversible and, thus, to require de novo synthesis of the enzyme. DISCUSSION The data presented in this paper demonstrate that PGI2 biosynthesis in cultured vascular endothelium results in deactivation of cyclooxygenase-hydroperoxidase but has no effect on the activity of PGI2 synthetase. This conclusion is based on the following lines of evidence. The finding that both untreated and aspirintreated endothelium respond maximally to multiple simulations by PGH2 suggests that PGI2 synthetase does not become deactivated as a result of the conversion of PGH2 to PGI2. Furthermore, the lack of a detectable effect of thrombin, A23187, or arachidonic acid on the capacity of the endothelium to produce PGI2 in response to subsequent stimulation by PGH2
shows that events or products generated during earlier steps in the biosynthetic pathway do not affect the activity of PGI2 synthetase. In light of these results, the observation that prior exposure of the endothelium to arachidonic acid markedly decreased the amount of PGI2 produced in response to subsequent stimulation by this fatty acid suggests that cyclooxygenase itself becomes deactivated as a result of the metabolism of arachidonic acid. Additional evidence in support of this conclusion is provided by the finding that other stimuli of PGI2 biosynthesis, such as thrombin and A23187, likewise decreased the responsiveness of the endothelium to arachidonic acid, and that prior exposure of the endothelium to arachidonic acid decreased the amount of PGI2 produced in response to subsequent stimulation by thrombin or A23187. In general, the capacity of the endothelium to produce PGI2 in response to subsequent stimulation was decreased proportionately to the magnitude of the initial response. To demonstrate conclusively that the actual metabolism of arachidonic acid by cyclooxygenasehydroperoxidase causes deactivation of this enzyme, studies with ibuprofen were carried out. The finding that ibuprofen effectively protected cyclooxygenase from deactivation during exposure to any given stimulus of PGI2 biosynthesis shows that the metabolism of arachidonic acid alone, and not events or products of earlier steps in the pathway causes deactivation of this enzyme.
Extensive studies of microsomal and purified preparations of prostaglandin cyclooxygenase-hydroperoxidase have shown that both the oxygenase (2, 21) and peroxidase (7, 8) activities become irreversibly deactivated during catalysis. Since autoinactivation occurs with several hydroperoxides in the absence of oxygenase reaction, Egan et al. (7, 8) have ascribed this phenomenon to attack on the enzyme by a species generated by the hydroperoxidase reaction. The ability of this oxidant to deactivate other enzymes, such as the hydroperoxidase itself (21) and PGI2 synthetase (9) , has also been established. Egan et al. (7, 8, 20, 21) have shown that deactivation of cyclooxygenase-hydroperoxidase is attenuated by a variety of reducing antioxidants. At micromolar concentrations, phenol (7) and organic sulfides, such as methyl-phenyl-sulfide (18, 20) , increase the extent and rate of both oxygenation of arachidonic acid by prostaglandin cyclooxygenase and reduction of hydroperoxides by the accompanying hydroperoxidase; higher concentrations are inhibitory. Likewise, both ascorbic acid and n-propyl gallate were found to enhance the formation of 6-ketoPGFia, apparently by shifting the metabolism of PGH2 from nonenzymic decomposition to enzymic formation of PGI2 (19) . In this case, the antioxidants were thought to act by protecting PGI2 synthetase from deactivation. Although the results of the present study demonstrate that deactivation of cyclooxygenase-hydroperoxidase occurs in cultured endothelium, it is not known whether deactivation of this enzyme in intact cells involves the same mechanism as that described for microsomal and purified preparations. In contrast to the effect of antioxidants in subcellular preparations, methyl-phenyl-sulfide, n-propyl gallate, and dithiothreitol markedly inhibit PGI2 production in a dosedependent relationship in endothelium, whereas neither ascorbic acid nor reduced glutathione has a significant effect. These findings may be interpreted to suggest that deactivation of cyclooxygenase in intact cells, such as cultured endothelium, does not involve attack on this enzyme by a peroxidase-dependent oxidant. Alternatively, inhibition of cyclooxygenase activity by antioxidants may result from a reduction in the level of endogenous hydroperoxide below that needed to initiate optimal catalysis (8, 21) .
Deactivation of cyclooxygenase markedly decreased the capacity of the endothelium to produce PGI2 for prolonged periods of time. The duration and magnitude of the effect of deactivation on the responsiveness of the endothelium to stimuli of PGI2 biosynthesis are comparable to the effects of aspirin. In this regard, the effects of deactivation appear to be irreversible; recovery of the capacity of the endothelium to produce PGI2 is likely to require de novo biosynthesis of the enzyme.
In conclusion, we suggest that the regulation of PG12 production in normal vascular endothelium may partly be a function of the activity and biosynthesis of cyclooxygenase-hydroperoxidase and that deactivation of this enzyme may be a primary factor limiting the capacity of the endothelium to produce PGI2. Studies are presently underway to characterize this phenomenon further in cultured endothelium and to determine whether deactivation occurs in vivo. Understanding of the mechanism of deactivation may permit the development of specific protective drugs.
